MYD88 and B-cell chronic lymphocytic leukemia: When focusing on IGHV-mutated CLL cases, patients with MYD88 mutations showed a tendency for shorter time to first treatment (TTFT) compared with patients with WT MYD8828, and no differences were observed in terms of OS28.